Stimwave Names Former Zimmer Biomet Exec New CEO

Stimwave Technologies Inc., a global medical device company that provides minimally invasive, MRI-compatible battery-free implantable devices to treat chronic pain, announced that Aure Bruneau has been named CEO, succeeding Paul LaViolette, effective immediately. LaViolette, who stepped into the role of Interim CEO in late 2019, will remain Chairman of the Board.
 
“Aure is a perfect match for the next fast-growth chapter at Stimwave,” said LaViolette. “He is a truly customer-centric leader and will continue our rapid expansion while creating a collaborative and success-oriented culture. Aure has been a magnet for talent, has driven both innovation and disciplined execution and is ideally suited to lead Stimwave.”
 
Bruneau brings over 20 years of medical device experience to the role, with specific experience in international management, business development, commercial leadership and new technology development. Most recently, Bruneau led the Robotic, CMF/Thoracic and Spine businesses of Zimmer Biomet where, as Group President, he oversaw an operation with $750 million annual revenues and 1,200 team members and business partners. During his Zimmer Biomet career, Bruneau led high-technology robotics development and commercialization, achieved first-in-class FDA approvals across multiple markets, created fast-growth innovations in surgery and new MIS procedures and built world-class teams and business processes. Prior to joining Zimmer Biomet, Bruneau held numerous leadership positions within Medtronic and Sofamor Danek.
 
“I am thrilled to have the opportunity to lead the Stimwave team, to help fulfill our mission to innovate in neuromodulation and provide unique solutions for patients with chronic pain. The Stimwave technology platform is one-of-a-kind and the company has had great success to date,” said Bruneau. “I am confident my passion for technology, business fundamentals, patients and the Stimwave team will help us achieve our clinical and business goals.”